SL-172154 by Shattuck Labs for Epithelial Ovarian Cancer: Likelihood of Approval

SL-172154 is under clinical development by Shattuck Labs and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SL-172154’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SL-172154 overview

SL-172154 is under development for the treatment of  colon cancer, advanced or metastatic ovarian cancer, epithelial ovarian cancer, cutaneous squamous cell carcinoma (CSCC), recurrent head and neck cancer squamous cell carcinoma, primary peritoneal cancer, fallopian tube cancer, hematological malignancies including acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). The drug candidates are based on Agonist Redirected Checkpoints (ARC) technology. The drug candidate is a two-sided human fusion protein incorporating the ECDs of SIRPα and CD40L, adjoined by a central Fc domain termed as SIRPα-Fc-CD40L. It is administered through intravenous and intratumor route.

Shattuck Labs overview

Shattuck Labs (Shattuck) a biotechnology company that develops bi-functional fusion proteins for the treatment of cancer and autoimmune disease. The company develops products using its proprietary agonist redirected checkpoint (ARC) platform and gamma delta T Cell engager (GADLEN) platform. Shattuck’s lead products include, SL-172154 (SIRPa-Fc-CD40L) developed for the treatment of ovarian cancer, cutaneous squamous-cell carcinoma (cSCC) and head and neck squamous cell carcinoma (HNSCC); and SL-279252 (PD1-Fc-OX40L) for advanced solid tumors and lymphoma. The company is also evaluating drugs targeting oncology, advanced solid tumors and autoimmune diseases. It operates a research and development office in Durham, North Carolina. Shattuck is headquartered in Austin, Texas, the United States.

For a complete picture of SL-172154’s drug-specific PTSR and LoA scores, buy the report here.